References
- Atalay C, Deliloglu Gurhan I, Irkkan C, Gunduz U. Mul-tidrug resistance in locally advanced breast cancer. Tumour Biol 2006; 27: 309–318.
- Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JGM, Wiemer EAC, et al. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug re-sistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic re-sponse. Clin Cancer Res 2003; 9: 827–836.
- Arnal M, Franco N, Fargeot P, Riedinger JM, Brunet-Lecomte P, Lizard-Nacol S. Enhancement of mdrl gene ex-pression in normal tissue adjacent to advanced breast cancer. Breast Cancer Res Treat 2000; 61: 13–20.
- Moureau-Zabotto L, Ricci S, Lefranc JP, Coulet F, Gen-estie C, Antoine M, et al. Prognostic impact of multidrug resist-ance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br J Cancer 2006; 94: 473–480.
- Larkin A, O'Driscoll L, Kennedy S, Purcell R, Moran E, Crown J, et al. Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. Int J Cancer 2004; 112: 286–294.
- Tsukamoto F, Shiba E, Taguchi T, Sugimoto T, Watanabe T, Kim SJ, et al. Immunohistochemical detection of P-glycopro-tein in breast cancer and its significance as a prognostic factor. Breast Cancer 1997; 4: 259–263.
- Filipits M, Pohl G, Rudas M, Dietze O, Lax S, Grill R, et al. Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Aus-trian breast and colorectal cancer study group. J Clin Oncol 2005; 23: 1161-1168.
- Surowiak P, Materna V, Matkowski R, Szczuraszek K, Ko- rnafel J, Wojnar A, et al. Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res 2005; 7: R862-R870.
- Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977; 35: 292–298.
- Sobin LH, Wittekind C, editors. International Union Against Cancer (UICC). TNM classification of malignant tumors. 5th edition. New York: John Wiley, 1997.
- Verrelle P, Meisonnier F, Fonck Y, Feillel V, Dionet C, Kwiatkowski F, et al. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carci-noma. J Natl Cancer Inst 1991; 83: 111–116.
- Botti G, Chiappetta G, D'Aiuto G, de Angelis E, de Mat-teis A, Montella M, et al. PCNA/cyclin and P-glycoprotein as prognostic factors in locally advanced breast cancer. An im-munohistochemical, retrospective study. Tumori 1993; 79: 214–218.
- Chung HC, Rha SY, Kim JH, Roh JK, Min JS, Lee KS, et al. P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 1997; 42: 65–72.
- Linn SC, Pinedo HM, van Ark-Otte J, van der Valk P, Hoekman K, Honkoop AH, et al. Expression of drug resistance proteins in breast cancer in relation to chemotherapy. Int J Can-cer 1997; 71: 787–795.
- Rudas M, Filipits M, Taucher S, Stranzl T, Steger GG, Jakesz R, et al. Expression of MRP1, LRP and Pgp in breast car-cinoma patients treated with preoperative chemotherapy. Breast Cancer Res Treat 2003; 81: 149–157.
- Vargas-Roig LM, Gago FE, Tello O, Martin de Civetta MT, Ciocca DR. C-erbB 2 (HER-2/neu) protein and drug resist-ance in breast cancer patients treated with induction chemother-apy. Int J Cancer 1999; 84: 129–134.
- Chevillard S, Lebeau J, Pouillart P, de Toma C, Beldjord C, Asselain B, et al. Biological and clinical significance of con-current p53 gene alterations, MDR1 gene expression, and 5-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res 1997; 3: 2471-2478.
- Trock BJ, Leonessa F, Clarke R. Multidrug-resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997; 89: 917–931.